Diagnostic challenges in cesarean scar ectopic pregnancy: case reports of rare entity

In: International Journal of Surgery Case Reports · 2026 · doi:10.1097/rc9.0000000000001323 · W7225996851
Case report OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-11-16 ⓘ

Two case reports illustrate cesarean scar ectopic pregnancy misdiagnosed as miscarriage, emphasizing the necessity of detailed ultrasound assessment to distinguish implantation location and prevent severe maternal morbidity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-16 · read from full text ⓘ

This case report describes two patients with cesarean scar ectopic pregnancy, a rare condition where implantation occurs within the defect of a prior uterine scar. The authors highlight diagnostic difficulties, noting that symptoms can mimic miscarriage and that misdiagnosis may lead to inappropriate management such as misoprostol administration, which delays necessary care. Both cases required emergency laparotomy for successful excision of the ectopic gestation, underscoring the importance of early transvaginal ultrasound and multidisciplinary surgical intervention to prevent hemorrhage or rupture. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction and importance: Cesarean scar ectopic pregnancy (CSEP) is a rare, potentially life-threatening condition characterized by implantation within or adjacent to a previous cesarean scar. Delayed or incorrect diagnosis may result in massive hemorrhage, uterine rupture, hysterectomy, loss of fertility, or maternal death. Presentation of cases: A 38-year-old gravida 3 para 2 with two previous cesarean deliveries presented at 17 weeks amenorrhea with lower abdominal pain worsened by intercourse. Transvaginal ultrasound showed a gestational sac implanted in the anterior lower uterine segment scar, without visible intervening myometrium between the sac and bladder. A 40-year-old gravida 7 para 6 with one previous cesarean delivery presented at 18 weeks with abdominal pain and vaginal bleeding. At 14 weeks, she had been diagnosed elsewhere with a presumed missed miscarriage and received misoprostol without expulsion of the pregnancy. Ultrasound subsequently demonstrated a non-viable CSEP. Both patients underwent emergency laparotomy and scar-pregnancy excision, followed by an uncomplicated recovery. Histopathology confirmed products of conception in Case 1 and placental tissue with acute chorioamnionitis in Case 2. Clinical discussion: CSEP can present variably and may be mistaken for an intrauterine miscarriage. Diagnosis requires careful assessment of the pregnancy’s relationship to the scar, uterine cavity, cervical canal, residual myometrium, and bladder. Miscarriage treatment should not begin until the location of the pregnancy is confirmed. Conclusion: Early recognition, referral, and detailed ultrasound are essential to reduce severe maternal morbidity, particularly where advanced imaging and interventional radiology are limited.
Full text 15,073 characters · extracted from oa-html · 5 sections · click to expand

Introduction

Cesarean scar ectopic pregnancy (CSEP) is a pregnancy implanted in or in close contact with a niche in a previous cesarean delivery scar. Although uncommon, it can progress toward the bladder and serosa, or into the uterine cavity, and is associated with major hemorrhage, uterine rupture, hysterectomy, and placenta accreta spectrum (PAS) if the pregnancy continues. The increasing number of cesarean deliveries makes reliable recognition of this condition increasingly relevant[]. HIGHLIGHTS Cesarean scar ectopic pregnancy (CSEP) remains a rare but increasingly encountered entity due to rising global cesarean section rates, necessitating heightened clinical vigilance. CSEP presents significant diagnostic challenges, with clinical manifestations ranging from asymptomatic cases to presentations that mimic miscarriage, thereby emphasizing the critical role of early transvaginal ultrasound. Misdiagnosis and inappropriate initial management (e.g., the use of misoprostol for a presumed miscarriage) can delay definitive care and increase the risk of complications such as hemorrhage and uterine rupture. Timely surgical intervention with histopathological confirmation offers effective management and favorable outcomes, highlighting the importance of individualized, multidisciplinary care. Diagnosis is primarily sonographic. Transvaginal ultrasound provides the best assessment of the implantation site and residual myometrium, while transabdominal ultrasound may be the initial examination and can complement the evaluation of the uterus, bladder, and hemoperitoneum. Standardized reporting should document the relationship of the pregnancy to the scar niche, uterine cavity, cervical canal, and bladder; residual myometrial thickness; embryonic cardiac activity; and peri-trophoblastic vascularity[,]. Evidence from a systematic review indicates substantially more severe morbidity when CSEP is diagnosed after 9 weeks rather than at or before 9 weeks[]. We present two surgically managed cases from Tanzania, including one initially treated with misoprostol for presumed missed abortion. The series highlights diagnostic pitfalls and practical management considerations where advanced imaging and interventional radiology may not be readily available. These case reports have been reported in line with the SCARE checklist[]. Patient and observation Case 1 A 38-year-old woman, Gravida 3, Para 2, Living 2, with a history of two previous cesarean deliveries, presented to the outpatient gynecology clinic in 2023 with a 17-week history of amenorrhea. Her chief complaint was lower abdominal pain, exacerbated by sexual intercourse. She denied vaginal bleeding, fever, gastrointestinal symptoms, urinary symptoms, or systemic complaints. Her obstetric history included two lower-segment cesarean sections: the first 6 years earlier for failure to progress, and the second 1-year earlier because of a previous cesarean scar. She had no known medical comorbidities apart from a documented allergy to sulfur-containing medications (she did not recall the exact medication). On examination, the patient was alert, oriented, afebrile, and hemodynamically stable. There were no signs of anemia or peripheral edema. Abdominal examination revealed a Pfannenstiel scar with localized suprapubic tenderness; bowel sounds were normal, and there was no rebound tenderness or guarding. Serum β-human chorionic gonadotropin (β-hCG) was 13 016 mIU/mL (laboratory reference: normal menstruating female < 5.3 mIU/mL; postmenopausal < 8.3 mIU/mL). Hemoglobin was 10.5 g/dL, white cell count was 4.80 × 109/L and platelet count was 413 × 109/L; her blood group was O positive. A transvaginal ultrasound (Fig. 1) demonstrated a gestational sac implanted within the anterior uterine wall at the site of the previous cesarean scar, with absent myometrial tissue between the sac and the bladder – consistent with a diagnosis of CSEP. The patient underwent an emergency laparotomy. Intraoperatively, an ectopic pregnancy was confirmed at the site of the previous uterine scar and was successfully excised. A single intramuscular dose of methotrexate (50 mg) was administered postoperatively as adjuvant therapy. Histopathological examination demonstrated chorionic villi lined by trophoblastic cells, confirming products of conception (Fig. 2A, B). Serial serum β-hCG monitoring demonstrated a progressive decline from 13 016 mIU/mL on admission to 2304 mIU/mL 2 days later and 405 mIU/mL 6 days after admission. Approximately 2 months later, the level was 0.84 mIU/mL, confirming biochemical resolution. Case 2 A 40-year-old gravida 7, para 6, with seven living children, presented after 18 weeks of amenorrhea with 4 days of progressively worsening lower abdominal pain and vaginal bleeding of approximately two pads per day. At 14 weeks of amenorrhea, she had been diagnosed at another healthcare facility with a presumed missed abortion and had received misoprostol. The pregnancy was not expelled. She reported no passage of tissue or foul-smelling discharge. She also reported dysuria without hematuria or urinary frequency. Her obstetric history included one cesarean delivery for malpresentation in a twin pregnancy, followed by five uncomplicated vaginal births. She was alert, pale, afebrile, and in mild distress from pain, but was hemodynamically stable. Abdominal examination demonstrated suprapubic tenderness without peritonism. Hemoglobin was 11.7 g/dL, white-cell count 8.87 × 109/L, platelet count 282 × 109/L and C-reactive protein 231.05 mg/L (laboratory reference range 0.5–5 mg/L); there was a low β hCG level of 7.46 mIU/mL (laboratory reference range: normal menstruating female, < 5.3 mIU/mL; postmenopausal, <8.3 mIU/mL), and her blood group was A positive. Initial treatment included intravenous crystalloid, paracetamol, and ceftriaxone–sulbactam 1500 mg given intravenously. Transvaginal ultrasound (Fig. 3) revealed a non-viable fetus implanted at the site of the previous cesarean scar, with characteristic findings of CSEP at approximately 14 weeks gestation. An emergency laparotomy was performed, during which a non-viable fetus was identified within the cesarean scar (Supplemental Digital Content Figure S1, available at: https://links.lww.com/IJSCR/A235). The ectopic gestation was surgically removed, and hemostasis was achieved. Histopathology showed immature chorionic villi, membranes, and decidual tissue with areas of infarction, hemorrhage, neutrophilic infiltration, and calcification (Supplemental Digital Content Figure S2 (A–C), available at: https://links.lww.com/IJSCR/A235); the reported impression was placental tissue with acute chorioamnionitis. Her postoperative recovery was reported as uncomplicated, and she was discharged in stable condition with follow-up arranged.

Discussion

CSEP, although the rarest variant of ectopic pregnancy, poses a substantial clinical challenge due to its often-subtle presentation and potentially life-threatening complications[]. CSEP results from implantation of the blastocyst within a microscopic defect or area of dehiscence at the site of a previous cesarean section scar. This defect may arise from poor healing, repeated cesarean deliveries, uterine instrumentation, or short interpregnancy intervals[]. Two distinct types of CSEP have been described based on the direction of trophoblastic invasion: Type I (endogenic) refers to pregnancies that grow toward the uterine cavity, while Type II (exogenic) involves implantation deep within the scar, growing outward toward the bladder or abdominal cavity. This classification has both diagnostic and prognostic value. Type I cases may progress to viable pregnancies, albeit with elevated risks, while Type II is associated with a higher likelihood of rupture and adverse maternal outcomes[]. Transvaginal ultrasound with color Doppler is the imaging modality of choice for early and accurate detection. Typical sonographic findings include a gestational sac located anteriorly at the level of the uterine isthmus, embedded at the site of a previous cesarean scar, with an empty uterine cavity and cervical canal. The myometrial layer between the bladder and gestational sac may be thinned or completely absent, and increased vascularity at the implantation site is often observed[]. In later gestation, fetal structures such as the yolk sac, fetal pole, or even cardiac activity may become visible. In cases where ultrasound findings are equivocal or when deep invasion is suspected, magnetic resonance imaging can provide additional detail, particularly in assessing the PAS, although it is not routinely indicated[]. There is no single optimal treatment for all cases of CSEP. Management should consider hemodynamic status, gestational age, cardiac activity, residual myometrial thickness, direction of growth, vascularity, reproductive preferences, expertise, and available resources. Current Society for Maternal-Fetal Medicine guidance recommends against expectant management, systemic methotrexate alone, and sharp curettage alone; it supports operative resection or ultrasound-guided uterine aspiration and considers intragestational methotrexate with or without other modalities[]. Contemporary syntheses likewise show heterogeneous evidence and emphasize tailoring treatment rather than selecting a universal approach[]. Both patients in this series underwent laparotomy. Open excision can provide rapid exposure, direct hemorrhage control, removal of the gestation, and repair of the scar defect, and may be reasonable for advanced or deeply implanted pregnancies, or where laparoscopy, hysteroscopy, and interventional radiology are unavailable. Case 1 received adjuvant methotrexate to ensure complete trophoblastic regression, as evidenced by declining β-hCG levels[]. These cases illustrate the variable clinical spectrum of CSEP and reinforce the importance of early recognition, appropriate imaging, and timely intervention. Multidisciplinary management involving obstetricians, radiologists, anesthesiologists, and, where necessary, interventional radiologists is essential to optimize outcomes and preserve reproductive potential.

Conclusion

CSEP is a rare but serious obstetric complication that requires a high index of suspicion, especially in women with a history of cesarean delivery. Early and accurate diagnosis, primarily through transvaginal ultrasound, is essential to prevent severe maternal morbidity and preserve fertility. Surgical management remains a safe and effective treatment option, particularly in advanced gestations or in symptomatic patients. Multidisciplinary care and timely intervention are key to optimizing patient outcomes and minimizing complications. Ethical approval Case report is exempted from ethical approval in my institution (The Aga Khan University, Medical college East Africa, Dar es Salaam, Tanzania). Consent Written informed consent was obtained from the patient for publication of this case series. A copy of the written consents are available for review by the Editor-in and Chief of this journal on request. accompanying images. Sources of funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Author contributions L.M., D.M.: Manuscript drafting, data collection. M.L.M., S.J.: Manuscript revision and patient management. C.N.: Histology interpretation. Z.F.: Radiology interpretation. Conflicts of interest disclosure The authors declare no competing interest. Research registration unique identifying number (UIN) Not applicable. Guarantor Not applicable. Provenance and peer review Not applicable. Patient perspective Both patients were glad of early detection of the condition and timely surgical interventions provided. Data availability statement Not applicable.

Acknowledgements

We dedicate this work to the late Dr. Wilbroad Kyejo, a compassionate Family Physician whose passion for research, mentorship, and service profoundly shaped our professional journeys. Dr. Kyejo was actively involved in the development of numerous manuscripts, including this case series, and his sudden passing left a void felt deeply by all who worked with him. His commitment to scientific inquiry and improving patient care continues to inspire us. We honour his memory with gratitude and respect, and we hope that this work reflects the spirit of dedication he embodied throughout his career.

References

[1] Betran A, Ye J, Moller A-B, et al. Trends and projections of caesarean section rates: global and regional estimates. BMJ Glob Health 2021;6:e005671.[2] Jordans IPM, Verberkt C, De Leeuw RA, et al. Definition and sonographic reporting system for Cesarean scar pregnancy in early gestation: modified Delphi method. Ultrasound Obstetrics Gynecol 2022;59:437–49.[3] Miller R, Gyamfi-Bannerman C. Society for maternal-fetal medicine consult series #63: cesarean scar ectopic pregnancy. Am J Obstet Gynecol 2022;227:B9–b20.[4] Salomon LJ, Alfirevic Z, Berghella V, et al. ISUOG practice guidelines (updated): performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstetrics Gynecol 2022;59:840–56.[5] Timor-Tritsch IE, Monteagudo A. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review. Am J Obstet Gynecol 2012;207:14–29.[6] Kerwan A, Al-Jabir A, Mathew G, et al. Revised Surgical CAse REport (SCARE) guideline: an update for the age of artificial intelligence. Prem J Sci 2025;10:100079.[7] Kang SY, Park BJ, Kim YW, et al. Surgical management of cesarean scar ectopic pregnancy: hysterotomy by transvaginal approach. Fertil Steril 2011;96:e25–8.[8] Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008;29:639–45.[9] Birch Petersen K, Hoffmann E, Rifbjerg Larsen C, et al. Cesarean scar pregnancy: a systematic review of treatment studies. Fertil Steril 2016;105:958–67.[10] Bouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod 2002;17:3224–30.[11] Seow KM, Huang LW, Lin YH, et al. Cesarean scar pregnancy: issues in management. Ultrasound Obstet Gynecol 2004;23:247–53.[12] Kaelin Agten A, Cali G, Monteagudo A, et al. The clinical outcome of cesarean scar pregnancies implanted “on the scar” versus “in the niche.” Am J Obstet Gynecol 2017;216:510.e1–.e6.[13] Alameddine S, Lucidi A, Jurkovic D, et al. Treatments for cesarean scar pregnancy: a systematic review and meta-analysis. J Maternal-Fetal Neonatal Med 2024;37:2327569.[14] Fu P, Sun H, Zhang L, et al. Efficacy and safety of treatment modalities for cesarean scar pregnancy: a systematic review and network meta-analysis. Am J Obstet Gynecol MFM 2024;6:101328.[15] Kłobuszewski B, Szmygin M, Nieoczym K, et al. Advances in treating cesarean scar pregnancy: a comprehensive review of techniques, clinical outcomes, and fertility preservation. Med Sci Monit 2024;30:e943550.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (14)

Source provenance

openalex
last seen: 2026-11-17T06:02:21.439193+00:00
License: CC0 · commercial use OK